Prostate Cancer Researchers Develop Personalized Genetic Test to Accurately Predict Recurrence Risk

Nov 12, 2014
Author: 
U of T researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy.

Prof. Bristow photo credit: UHN

U of T researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy.

The findings are published online in Lancet Oncology. Professor Robert Bristow of the departments of Radiation Oncology and Medical Biophysics, and Assistant Professor Paul Boutros, of Medical Biophysics, report that the gene test provides a much-needed quick and accurate tool to determine with greater precision the men who will do well with local treatment only (surgery or radiation), and those who will need extra treatment (chemotherapy and hormone therapy) to ensure the cancer is completely eradicated.   Bristow talks about the research here

“Our findings set the stage to tackle the ongoing clinical problem of under-treating men with aggressive disease that will recur in 30 to 50 per cent of patients due to hidden, microscopic disease that is already outside the prostate gland during initial treatment,” says Bristow, a clinician-scientist at Princess Margaret Cancer Centre.

“This genetic test could increase cure rates in intermediate- to high-risk men by preventing progression to this metastatic spread of prostate cancer.”

The next step will be testing the gene signature on many more patients worldwide for three to five years to turn the test into one that is readily available in the clinic to guide personalized prostate cancer treatments.  

The predictive test analyses biopsy tissue taken before treatment even starts to identify abnormal genetic characteristics (abnormal DNA) of the prostate cancer and its oxygen content. Low oxygen, or hypoxia, is an already known factor in the spread of prostate cancer. Together, this information can predict with almost 80 per cent accuracy – and in about three days – those prostate cancer patients who are at greatest risk of their disease returning, the study shows.

“The clinical potential is enormous for thousands of patients,” says Bristow. “This is personalized cancer medicine to the hilt – the ability to provide more targeted treatment to patients based on their unique cancer genetic fingerprint plus what’s going on in the cancer cell’s surrounding environment. We hope to improve cure rates by reducing the chances of the cancer recurring and prevent the cells from spreading.”

The researchers developed the genetic test with two groups of patients. In the first group, the team analyzed DNA from initial diagnostic biopsies of 126 men who were treated with image-guided radiotherapy (IGRT) and followed for an average 7.8 years. In the second group, the team used the test on 150 men whose tumours were removed surgically (radical prostatectomy). The genetic test produced similar results in both groups and therefore can be used in patients who choose radiotherapy or surgery as their initial treatment. 

The researchers further found that when testing tumours for hypoxia in the men treated with IGRT and the gene test, this combined information made the test even more accurate, says Bristow.

The study showed that the men with the best outcomes – lower than seven per cent recurrence of prostate cancer at five years – had low levels of genetic changes and low hypoxia. For men with high levels of genetic changes and high hypoxia, outcomes were worse – more than 50 per cent of patients had recurrence and these are men who, in the future, could be offered intensified treatment as part of a personalized treatment plan.

Bristow and Boutros also co-lead the Canadian Prostate Cancer Genome Network (CPC-GENE) Sequencing Project.


Funding was provided by Prostate Cancer Canada, the Movember Foundation, the Ontario Institute for Cancer Research, and The Princess Margaret Cancer Foundation. The study was conducted with assistance from the Wellcome Trust Clinical Research Facility, Addenbrooke’s Clinical Research Centre, Cambridge, U.K.
 

Tweets

UofT Medicine
@uoftmedicine
Childhood rates are on the rise & the global debate about a tax on sugary drinks is anything but sweet -… https://t.co/OQ2bDK5Ao6
UofT Medicine
@uoftmedicine
If your kid is itching to join a team this season, here’s what you should know about risks… https://t.co/BzpYJ11SXv
UofT Medicine
@uoftmedicine
“I want to be a scientist first — but where you see inequities, you need to be an advocate. I don’t think they’re s… https://t.co/Z4wPxpkLHO

UofTMed Magazine

Burnout, suicide, depression, and the emotional effects of mistakes. We address physician wellness in the next issue of UofTMed magazine, out May 30.

Sign up for your free digital copy.
Back to Top